Related Experiment Video
Updated: Jul 1, 2026
12:50
Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
Published on: September 15, 2017
6.7K
Anti-Inflammatory Peptide Prevents Aβ25-35-Induced Inflammation in Rats via Lipoxygenase Inhibition
Yudhishthir Yadav1, Masroor Anwar1, Hanuman Sharma2
1Department of Biophysics, All India Institute of Medical Sciences, New Delhi 110029, India.
Cells
|July 11, 2025
Summary
The lipoxygenase inhibitor peptide YWCS improved cognitive function and reduced Alzheimer's disease (AD) markers in a rat model. YWCS shows potential as a therapeutic agent for AD by targeting neuroinflammation.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Neuroinflammation mediated by lipoxygenase (LOX) is implicated in Alzheimer's disease (AD) progression.
- Overexpression of LOX-5 is observed in patients with AD serum, suggesting its critical role.
- Amyloid-beta (Aβ) peptide is a key component in AD pathogenesis.
Purpose of the Study:
- To evaluate the therapeutic efficacy of the LOX-inhibitor-peptide YWCS in an Aβ25-35-induced rat model of Alzheimer's disease.
- To investigate the effects of YWCS on cognitive function, neuroinflammation, and key AD biomarkers.
- To assess the potential of YWCS as a novel treatment strategy for AD.
Main Methods:
- Induction of AD in rats using Aβ25-35 injection.
- Administration of the LOX-inhibitor-peptide YWCS.
- Assessment of cognitive function through behavioral tests (open field, novel object recognition, elevated plus maze, Morris water maze).
- Magnetic resonance imaging (MRI) for hippocampal analysis.
- Molecular analyses including Western blotting and immunofluorescence staining for AD biomarkers and inflammatory markers.
- Measurement of serum LOX levels.
Main Results:
- YWCS treatment significantly enhanced cognitive performance in multiple behavioral tests.
- Molecular analysis revealed that YWCS modulated the expression of LOX-5, LOX-12, Aβ, γ-secretase components, p-Tau181, Akt, p-Akt, and p53.
- Immunofluorescence confirmed reduced expression of LOX, Aβ, and p-Tau181 in the hippocampus following YWCS treatment.
- Serum LOX levels were significantly decreased by YWCS treatment, consistent with human AD patient data.
- MRI scans showed no hippocampal shrinkage in YWCS-treated rats, suggesting a protective effect.
Conclusions:
- The LOX-inhibitor-peptide YWCS demonstrates significant therapeutic potential for Alzheimer's disease.
- YWCS effectively improves cognitive deficits and regulates key inflammatory and AD-related molecular markers.
- Targeting LOX with YWCS offers a promising strategy to counteract neuroinflammation and disease progression in AD.
